The evolving locally-advanced non-small cell lung cancer landscape: Building on past evidence and experience

Critical Reviews in Oncology/Hematology

Volumn 96, Issue 2, 2015, Pages 319-327

  Méry, Benoite ^a   Guy, Jean Baptiste ^a   Swalduz, Aurélie ^a   Vallard, Alexis ^a   Guibert, Cyril ^a   Almokhles, Hweej ^a   Mrad, Majed Ben ^a   Rivoirard, Romain ^a   Falk, Alexander T ^b   Fournel, Pierre ^a   Magné, Nicolas ^a  

^a INSTITUT DE CANCÉROLOGIE LUCIEN NEUWIRTH   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Concomitant chemo radiotherapy; Immunotherapy; Locally advanced non small cell lung cancer; Proton radiotherapy; Radiotherapy; Targeted therapies

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; COBALT 60; ERLOTINIB; GEFITINIB; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PLACEBO; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; THALIDOMIDE; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COBALT TELETHERAPY; COMPUTER ASSISTED RADIOTHERAPY; DRUG RESEARCH; HUMAN; INTENSITY MODULATED RADIATION THERAPY; KARNOFSKY PERFORMANCE STATUS; META ANALYSIS (TOPIC); MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NON SMALL CELL LUNG CANCER; ORGANS AT RISK; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTON THERAPY; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SURVIVAL TIME; TREATMENT PLANNING; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOTHERAPY; LUNG NEOPLASMS; PROCEDURES; RADIOTHERAPY;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DOSE FRACTIONATION; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; RADIOTHERAPY;

EID: 84955169311     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.05.020     Document Type: Review

References (80)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study ofconcurrent versus sequential thoracic radiotherapy in combinationwith mitomycin, vindesine, and cisplatine in unresectable stage IIInon-small-cell lung cancer. J Clin Oncol 1999;17(September (9)):2692-9.
3. Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of con-comitant versus sequential radiochemotherapy in locally advancednon-small-cell-lung cancer. J Clin Oncol 2010;28:2181-90.
4. Cartier L, Fournel P. Principes et traitements par chimiothérapie etradiothérapie des cancers bronchiques non à petites cellules EMC. Pneumologie 2009;6, 002-L-12.
5. Wang T, Nelson RA, Bogardus A, Grannis Jr FW. Five-year lung cancersurvival: which advanced stage nonsmall cell lung cancer patients attainlong-term survival? Cancer 2010;116:1518-25.
6. Schiller JH, Harrington D, Belani CP, et al. Eastern Cooperative Oncol-ogy Group: comparison of four chemotherapy regimens for advancednon-small-cell lung cancer. N Engl J Med 2002;346:92-8.
7. De Ruysscher D, Botterweck A, Dirx M, et al. Eligibility for con-current chemotherapy and radiotherapy of locally advanced lungcancer patients: a prospective, population-based study. Ann Oncol2009;20:98-102.
8. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epider-mal growth factor receptor underlying responsiveness of non-small-celllung cancer to gefitinib. N Engl J Med 2004;350(21):2129-39.
9. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinaseinhibition in non-small-cell lung cancer. N Eng J Med 2010;363(18):1693-703.
10. Goldstraw P, Crowley J, Chansky K, et al. International Association forthe Study of Lung Cancer International Staging Committee: Participat-ing Institutions. The IASLC Lung Cancer Staging Project: proposalsfor the revision of the TNM stage groupings in the forthcoming (sev-enth) edition of the TNM Classification of malignant tumours. J ThoracOncol 2007;2(8):706-14.
11. Rami-Porta R, Ball D, Crowley J, et al. International Staging Commit-tee; Cancer Research and Biostatistics; Observers to the Committee;Participating Institutions. The IASLC Lung Cancer Staging Project:proposals for the revision of the T descriptors in the forthcoming (sev-enth) edition of the TNM classification for lung cancer. J Thorac Oncol2007;2(7):593-602.
12. Beahrs OH, Henson DE, Hutter RVP, et al. American Joint Commit-tee on Cancer Manual for Staging of Cancer. Philadelphia, PA: JBLippincott Co; 1992.
13. Freise G, Gabler A, Liebig S. Bronchial carcinoma and long-termsurvival. Thorax 1978;33:228-34.
14. Detterbeck F. What to do with surprise N2?: intraoperative manage-ment of patients with non-small cell lung cancer. J Thorac Oncol2008;3(3):289-302.
15. Detterbeck FC. Maintaining aim at a moving target. J Thorac Oncol2011;6(3):417-22.
16. De Leyn P, Dooms C, Kuzdzal, et al. Revised ESTS guidelines forpreoperative mediastinal lymph node staging for non-small-cell lungcancer. Eur J Cardiothorac Surg 2014;45:787-98.
17. Lardinois D, De Leyn P, Van Schil P, et al. ESTS guidelines for intra-operative lymph node staging in non-small cell lung cancer. Eur JCardiothorac Surg 2006;30:787-92.
18. Kang CH, Ra YJ, Kim YT, et al. The impact of multiple metastatic nodalstations on survival in patients with resectable N1 and N2 nonsmall-celllung cancer. Ann Thorac Surg 2008;86:1092-7.
19. Kozower BD, Larner JM, Detterbeck FC, et al. Special treatment issuesin non-small cell lung cancer: diagnosis and management of lung can-cer, 3rd ed: American College of Chest Physicians evidence-basedclinical practice guidelines. Chest 2013;143:e369S.
20. Yildizeli B, Fadel E, Mussot S, et al. Morbidity, mortality, and long-term survival after sleeve lobectomy for non-small-cell lung cancer. Eur J Cardiothorac Surg 2007;31:95-102.
21. Price A. Emerging developments of chemoradiotherapy in stage IIINSCLC. Nat Rev Clin Oncol 2012;9:591-8.
22. Curran Jr WJ, Paulus R, Langer CJ, et al. Sequential vs. concurrentchemoradiation for stage III non-small-cell lung cancer: randomizedphase III trial RTOG 9410. J Natl Cancer Inst 2011;103:1452-60.
23. Salama JK, Vokes EE. New radiotherapy and chemoradiotherapyapproaches for non-small-cell lung cancer. J Clin Oncol 2013;31:1029-38.
24. Non-small Cell Lung Cancer Collaborative Group. Chemotherapyin non-small cell lung cancer: a meta-analysis using updated dataon individual patients from 52 randomized clinical trials. BMJ1995;311:899-909.
25. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clin-ical Oncology treatment of unresectable non-small-cell lung cancerguideline: updated 2003. J Clin Oncol 2004;22:330-53.
26. Barlesi F, Pujol JL, Daures JP. Should chemotherapy for advanced non-small cell lung cancer be platinum-based? A literature based meta-analysis of randomized trials. 2005 ASCO annual meeting proceedings. J Clin Oncol 2005;23(16S (June 1 Suppl.)):7213, 673s.
27. O'Rourke M, Roqué I, Figuls N, Farré Bernado, Macbeth F. Concurrentchemoradiotherapy in non-small cell lung cancer. Cochrane DatabaseSyst Rev 2010;16:CD002140.
28. Marino P, Preatoni A, Cantoni A. Randomized trials of radiothe-rapy alone versus combined chemotherapy and radiotherapy in stagesIIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer1995;76(4):593-601.
29. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy comparedwith radiotherapy alone in the treatment of locally advanced, unre-sectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med1996;125(9):723-9.
30. Gandara D, Narayan S, Lara Jr PN, et al. Integration of novel thera-peutics into combined modality therapy of locally advanced non-smallcell lung cancer. Clin Cancer Res 2005;11:5057s-62s.
31. Gadgeel SM, Ruckdeschel JC, Patel BB, et al. Phase II study of peme-trexed and cisplatin, with chest radiotherapy followed by docetaxelin patients with stage III non-small-cell lung cancer. J Thorac Oncol2011;6(5):927-33.
32. Arriagada R, Le Chevalier T, Quoix E, et al. ASTRO plenary: effectof chemotherapy on locally advanced non-small cell lung carcinoma: arandomized study of 353 patients. GETCB (Groupe d'étude et Traite-ment des Cancers Bronchiques), FNCLCC (Federation Nationale desCentres de Lutte contre le Cancer) and the CEBI trialists. Int J RadiatOncol Biol Phys 1991;20:1183-90.
33. Bradley JD, Bae K, Graham MV, et al. Primary analysis of the phaseII component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapyfor patients with inoperable non-small-cell lung cancer: RTOG 0117. JClin Oncol 2010;28:2475-80.
34. Perez CA, Pajak TF, Rubin P, et al. Long-term observations of thepatterns of failure in patients with unresectable non-oat cell carcinomaof the lung treated with definitive radiotherapy. Report by the RadiationTherapy Oncology Group. Cancer 1987;59:1874-81.
35. Fang LC, Komaki R, Allen PK, et al. Comparison of outcomes forpatients with medically inoperable stage I non-small-cell cancer treatedwith two-dimensional vs. three-dimensional radiotherapy. Int J RadiatOncol Biol Phys 2006;66:108-16.
36. Zinner RG, Komaki R, Cox JD, et al. Dose escalation of gemcitabineis possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage IIInon-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2009;73:119-27.
37. Aupérin A, Le Péchoux C, Pignon JP, et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis ofindividual data from 1764 patients. Ann Oncol 2006;17:473-83.
38. Rigas JR, Kelly K. Current treatment paradigms for locally advancednon-small cell lung cancer. J Thorac Oncol 2007;2(Suppl 2):S77-85.
39. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versuscombined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. JNatl Cancer Inst 1991;83:417-23.
40. Machtay M, Paulus R, Moughan J, et al. Defining local-regional controland its importance in locally advanced non-small cell lung carci-noma: a Radiation Therapy Oncology Group analysis. J Thorac Oncol2012;7:716-22.
41. Groen HJ, van der Leest AH, Fokkema E, et al. Continuouslyinfused carboplatin used as radiosensitizer in locally unresectablenon-small-cell lung cancer: a multicentre phase III study. Ann Oncol2004;15:427-32.
42. Martel MK, Ten Haken RK, Hazuka MB, et al. Estimation of tumorcontrol probability model parameters from 3-D dose distributions ofnon-small cell lung cancer patients. Lung Cancer 1999;24:37-47.
43. Bradley JD, Paulus R, Komaki R, et al. A randomized phase IIIcomparison of standard dose (60 Gy) versus high dose (74 Gy) con-formal chemoradiotherapy with or without cetuximab for stage IIINSCLC: Results on radiation dose in RTOG 0617. J Clin Oncol2013;31:abstr7501.
44. Suwinski R, Withers HR. Time factor and treatment strategies in sub-clinical disease. Int J Radiat Biol 2003;79:495-502.
45. Fowler JF. 21 years of biologically effective dose. Br J Radiol2010;83:554-68.
46. Mauguen A, Le Pechoux C, Saunders MI, et al. Hyperfractionated oraccelereated radiotherapy in lung cancer: an individual patient datametaanalysis. J Clin Oncol 2012;30:2788-97.
47. Vansteenkiste J, De Ruysscher D, Eberhardt WE, et al. Early andlocally advanced non-small-cell lung cancer (NSCLC): ESMO Clin-ical Practice Guidelines for diagnosis, treatment and follow-up. AnnOncol 2013;24(Suppl 6):vi89-98.
48. Gautschi O, Gumerlock PH. Recent advances in the biology of lungcancer. In: Hansen HH, editor. Lung cancer therapy. Philadelphia, PA:Taylor and Francis Ltd.; 2006.
49. Gandara DR, Gumerlock PH. Epidermal growth factor receptor tyrosinekinase inhibitors plus chemotherapy: case closed or is the jury still out. J Clin Oncol 2005;23:5856-8.
50. Kelly K, Gaspar LE, Chansky K, et al. Low incidence of pneumonitison SWOG 0023:a preliminary analysis of an ongoing phase III trialof concurrent chemoradiotherapy followed by consolidation docetaxeland gefitinib/placebo maintenance in patients with inoperable stage IIInon-small-cell lung cancer. J Clin Oncol 2005;23:634a.
51. Goldberg Z, Gaspar LE, Lara P, et al. Combined modality treatment ofnon-small cell lung cancer. Lung Cancer Updates 2001;1:1-11.
52. Provencio M, Sanchez A, Garrido P, et al. New molecular targetedtherapies integrated with radiation therapy in lung cancer. Clin LungCancer 2010;11(2):91-7.
53. Hoang T, Dahlberg S, Schiller J et al. Randomized phase III study ofthoracic radiation in combination with paclitaxel and carboplatin withor without thalidomide in patients with stage III non-small-cell lungcancer: The ECOG 3598 Study. J Clin Oncol 30:616-622.
54. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximabfor locoregionally advanced head and neck cancer: 5-year survivaldata from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11(1):21-8.
55. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plusa monoclonal antibody against HER2 for metastatic breast cancer thatoverexpresses HER2. N Engl J Med 2001;344:783-92.
56. Pao W, Miller V, Zakowski M, et al. EGF recptor gen mutations arecommon in lung cancer from never smokers and are associated withsensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA2004;101:13306-11.
57. Gandara DR, West H, Chansky K, et al. Bronchioloalveolar carcinoma:a model for investigating the biology of EGFR inhibition. Clin CancerRes 2004;10:4205-9.
58. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung can-cer: correlation with clinical response to gefitinib therapy. Science2004;304:1497-500.
59. Tracy S, Mukohara T, Hansen M, et al. Gefitinib induces apoptosis inthe EGFRL858R non-small-cell lung cancer cell line H3255. CancerRes 2004;64:7241-4.
60. Gumerlock PH, Pryde BJ, Kimura T, et al. Enhanced cytotoxicityof docetaxel OSI-774 combination in non-small cell lung carcinoma(NSCLC). Proc Am Soc Clin Oncol 2003;22:662.
61. Solit DB, She Y, Moasser M, et al. Pulsatile administration of the epi-dermal growth factor receptor inhibitor gefitinib is significantly moreeffective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res 2005;11:1983-9.
62. Brahmer JR, Pardoll DM. Immune Checkpoint Inhibitors: makingimmunotherapy a reality for the treatment of lung cancer. CancerImmunol Res 2013;1(July (2)):85-91.
63. Brahmer JR. Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol 2013;31:1021-8.
64. Ramnath N, Tan D, Li Q, et al. Is downregulation of MHC classI antigen expression in human non-small-cell lung cancer associ-ated with prolonged survival. Cancer Immunol Immunother 2006;55:891-9.
65. Marincola FM, Jaffee EM, Hicklin D, Ferrone S. Escape of human solidtumors from T-cell recognition: molecular mechanisms and functionalsignificance. Adv Immunol 2000;74:181-273.
66. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligandfor PD-1 and inhibits T cell activation. Nat Immunol 2001;2:261-8.
67. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agentanti-programmed death-1 (MDX-1106) in refractory solid tumors:safety, clinical activity, pharmacodynamics, and immunologic corre-lates. J Clin Oncol 2010;28:3167-75.
68. Rizvi N. A phase 1 study of nivolumab (anti-PD-1; BMS-936558;ONO-4538) + platinum-based doublet chemotherapy (Pt-doublet) inChemotherapy-naïve non-small cell lung cancer patients. J Clin Oncol2013;31(Suppl) (abbstr 8072).
69. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumabin advanced melanoma. N Engl J Med 2013;369(July (2)):122-33, http://dx.doi.org/10.1056/NEJMoa1302369.
70. Hamid O, Robert C, Daud A, et al. Safety and tumorresponses with Lambrolizumab (Anti-PD-1) in Melanoma. NEngl J Med 2013;369(June (2)):134-44, http://dx.doi.org/10.1056/NEJMoa1305133.
71. Verbakel WFAR, van Reij E, Ladenius-Lischer I, Cuijpers JP, SlotmanBJ, Senan S. Clinical application of a novel hybrid intensity-modulatedradiotherapy technique for stage III lung cancer and dosimetric com-parison with four other techniques. Int J Radiat Oncol Biol Phys2012;83:e297-303.
72. Quan EM, Chang JY, Liao Z, et al. Automated volumetric modulatedArc therapy treatment planning for stage III lung cancer: how does itcompare with intensity-modulated radio-therapy. Int J Radiat OncolBiol Phys 2012;84:e69-76.
73. Chang JY, Zhang X, Wang X, et al. Significant reduction of normaltissue dose by proton radiotherapy compared with three-dimensionalconformal or intensity modulated radiation therapy in stage I orstage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys2006;65:1087-96.
74. Bush DA, Slater JD, Shin BB, et al. Hypofractionated proton beamradiotherapy for early-stage lung cancer. Chest 1999;116:1313-9.
75. Bush DA, Slater JD, Shin BB, et al. Hypofractionated proton beamradiotherapy for stage I lung cancer. Chest 2004;126:1198-203.
76. Iwata H, Murakami M, Demizu Y, et al. High dose proton therapyand carbon-ion therapy for stage I non-small-cell lung cancer. Cancer2010;116:2476-85.
77. Nihei K, Ogino T, Ishikura S, et al. High dose proton beam therapyfor stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys2006;65:107-11.
78. Chang JY, Komaki R, Wen HY, et al. Toxicity and patterns of failure ofadaptative/ablative proton therapy for early-stage, medically inoperablenon-small cell lung cancer. Int Radiat Oncol Biol Phys 2011;80:1350-7.
79. Sejpal S, Komaki R, Tsao A, et al. Early findings on toxicity of protonbeam therapy with concurrent chemotherapy for non small cell lungcancer. Cancer 2011;117:3004-13.
80. Chang JY, Komaki R, Lu C, et al. Phase 2 study of high dose protontherapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer 2011;117:4707-13.